Onco-Innovations Limited (NEO:ONCO)
0.2000
0.00 (0.00%)
Nov 6, 2026, 12:33 PM EST
Onco-Innovations Revenue
Onco-Innovations had revenue of 90.88K CAD in the twelve months ending July 31, 2026, up 7.18% year-over-year. In the fiscal year ending April 30, 2026, Onco-Innovations had annual revenue of 110.38K with 69.06% growth. That makes Onco-Innovations the 46,443rd largest company in the world by revenue and 1,077th in Canada.
Revenue (ttm)
90.88K
Revenue Growth
+7.18%
P/S Ratio
152.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | 110.38K | 45.09K | 69.06% |
| Apr 30, 2025 | 65.29K | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Onco-Innovations News
- 6 weeks ago - Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform - Accesswire
- 7 weeks ago - Onco-Innovations Announces Closing of Shares for Debt Settlement - TheNewswire
- 1 month ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. - GlobeNewsWire
- 2 months ago - Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species - TheNewswire
- 2 months ago - Onco-Innovations Announces Shares for Debt Settlement - TheNewswire
- 2 months ago - Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program - Accesswire
- 2 months ago - Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update - TheNewswire
- 3 months ago - Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010 - TheNewswire